U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/661,780 Filing Date 09/15/2003 INFORMATION DISCLOSURE First Named Inventor PHILIPPE BOUCHARD STATEMENT BY APPLICANT Art Unit 1614 Examiner Name Brian Yong S. Kwon (Use as many sheets as necessary) 3 Attorney Docket Number 098501-0305998

U. S. PATENT DOCUMENTS						
Examiner nitials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		us 6,077,523	06/20/2000	Romano Deghenghi		
		US- 6,022,860	02/08/2000	Engel et al.		
		US-				
***************************************		US-				
		US-				
		US-				
		US-			que mais en como en guarror menos en manos en manor en manor el ball del la cado (Mel dendas e Referado (Mel Africa Hel Mel Mel Mel Mel Mel Mel Mel Mel Mel M	
per ng Japanggalandan 1991, gipungganian		US-				
		US-	PA			
		US-	alari er kummut et mintut er mintut e kalament et arvallikusta erak blev invelikusti, veidebbbbb (COM et belekki	e (1994) e essent (1984) (1984) e en e	(Agada) (TTAB) BARAD (ARAKO ARAKA PERSENCANAN PERSENTAL PARA) PERSENTALAN ARAK PERSENTALAN PER	
ill incomplete of publications	· practicular description	US-				
And difference of the latest description of	and and market	US-		AND THE RESERVE OF THE PROPERTY OF THE PROPERT	a ann an Aireann an Aireann ann an Aireann an Aireann an Aireann An Aireann An Aireann An Aireann An Airean Ai	
		US-	######################################			
		US-				
		US-			THE STATE OF THE PARTY OF THE P	
PART - A COMPANY PROFIT OF THE PARTY OF THE	<u> </u>	US-		en auma de Paris de la competito de la competi	gayayayay in dibinayay ay	
AND THE PARTY OF T	- hours assertances	US-				
	·	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Τ <sup>6</sup>		
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			or Relevant Figures Appear	H		
			******************************		dsyyrabsanyrsta quandeson stattodada bsyktäddi buta nbe			
	. 2444 -+>2116		egy épa é ndagaja é emaddia y trada é agé agu	***************************************	@&************************************			
•								
<b></b>			yyrr,p4,449********************************	**************************************	} } } > > > > > = + + + + + + + + + + + + + +			

Examiner	 Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspio.gov">www.uspio.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/661,780	
INFORMATION DISCLOSURE				Filing Date	09/15/2003	
STATEMENT BY APPLICANT (Use as many sheets as necessary)			CANT	First Named Inventor	PHILIPPE BOUCHARD	
				Art Unit	1614	
				Examiner Name	Brian Yong S. Kwon	
Sheet	2	of	3	Attorney Docket Number	098501-0305998	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		NESTOR, JR. ET AL., "Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity," J. Med. Chem., Institute of Bio-Organic Chemistry, Vol. 35 (No. 21), p. 3942-3948, (October 16, 1992).	.,			
***************************************		DEGHENGHI ET AL., "Antarelix (EP 24332) a novel water soluble LHRH antagonist," Biomed. Pharmacother., Europeptides (Argenteuil, France), Vol. 47 (No. 2-3), p. 107-110, (1993).				
***************************************		RIVIER ET AL., "Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6," J. Med. Chem., Salk Institute for Biological Studies (La Jolla, California), Vol. 35 (No. 23), p. 4270-4278, (November 13, 1992).				
41 075 ) 1 1 1 4 7 7 7 7 7 1 1 1 1 1 1 1 1 1 1 1	See Attachm 1					
A LIVERS CONTRACTOR STATES		HAVIV ET AL., "In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormone," J. Med. Chem., TAP Pharmaceuticals, Inc. (Abbott Park, IL), Vol. 37 (No. 5), p. 701-705, (March 4, 1994).				
		WEINBAUER ET AL., "Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis)," Andrologia, Institute of Reproductive Medicine of the University (Munster, Germany), Vol. 25 (No. 3), p. 141-147, (May-June 1993).	·2 E42(() *** 17			
	an miqueenistik					

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Addendum

## Page 3 of 3

## Attachment 1

a.

b. STOECKEMANN ET AL., "Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin or dimethylbenz[]anthrracene-induced mammary carcinoma: studies with slow-release formulations," J. Cancer Res. Clin. Oncol., Hoechst AG, Pharma-Research (Frankfurt/Main, Germany), Vol. 119 (No. 8), p. 457-462, (1993).

c.